Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.

It's a sign that confidence in the company's future is low, perhaps reflecting worries about the impending expirations of patents on its cancer-fighting Ibrance, blood thinner Eliquis, and pneumonia ...

Wall Street closed in the green on Friday after the September nonfarm payrolls report came in cooler than economists expected. The blue-chip Dow ended up 0.5%, the benchmark S&P 500 gained 0.7%, and ...

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous ...

VACCINE LAWSUIT  Florida's Attorney General is suing a major drugmaker, saying it misled patients about the benefits of its ...

Florida Attorney General James Uthmeier filed a lawsuit against Pfizer Inc. this week, accusing the pharmaceutical giant of ...

Pfizer's tilrekimig met the Phase II endpoint in atopic dermatitis, improving Week 16 EASI-75 responses across doses versus ...

Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management ...

Florida Attorney General James Uthmeier is suing Pfizer and CEO Albert Bourla, alleging the company misled consumers about ...

Pfizer is making moves on the dermatology and wider immunology fronts, detailing two phase 3 wins for its oral Janus kinase inhibitor, Litfulo, and a promising phase 2 update for its investigationa | ...